Mark Rasnake, MD
Infectious Disease · Knoxville, TNNPI 1962464644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $783 and has fallen 97.5% since, to $20 in 2024.
Across 87 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$315
- Merck$240
- Johnson & Johnson$142
- Insmed, Inc.$121
- Angiodynamics, Inc.$115
- Pfizer$91
- plus $466 from 15 others
Across 2 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$9K
What the payments were for
- Food & beverage$1,35391%
- Education$1379%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $315 |
| Merck | 15 | $240 |
| Johnson & Johnson | 11 | $142 |
| Insmed, Inc. | 6 | $121 |
| Angiodynamics, Inc. | 1 | $115 |
| Pfizer | 6 | $91 |
| Janssen Products, LP | 1 | $65 |
| Astellas Pharma US Inc | 3 | $65 |
| AstraZeneca(2 entities) | 4 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Novartis | 3 | $36 |
| Amgen | 2 | $33 |
| Mylan Specialty L.p. | 2 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| Atricure, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$115
How this compares
$1,490 in reported general payments places this provider in the 65th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $101,205 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $30,746 |
| Entecavir | 12 | $3,607 |
| Methenamine Hippurate | 26 | $840 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Knoxville
- Raul Vasquez GaragattiKnoxville$9K
- Simi VincentKnoxville$7K
- James WangKnoxville$2K
- John NarroKnoxville$2K
- Bryan WalkerKnoxville$2K
- Ernest KempKnoxville$1K
- John AdamsKnoxville$1K
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Mark PierceCookeville$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.